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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.02.005A 10-year-old boy presented with right proptosis for 8 months. The eyeball was grossly pushed down,
with diffuse corneal haze and non-reactive pupil. Systemic examination was normal. Previous investiga-
tions in another centre included a computerized tomography scan, which showed a well-defined enhanc-
ing retro-bulbar mass, a non-contributory fine needle aspiration cytology and a biopsy showing
fibrocollagenous tissue with moderate lympho-monocytic infiltrate suggestive of non-specific inflamma-
tion. PET-CT scan revealed the presence of enlarged fluoro-deoxyglucose-avid cervical and mesenteric
lymph nodes. Biopsy of the retro-bulbar mass was repeated in our centre. It showed fibrocollagenous
and skeletal muscle tissue infiltrated by lymphoid follicles, dispersely lying lymphocytes and plasma cells,
and admixed large atypical cells with vesicular nuclei, prominent nucleoli and scanty cytoplasm, strongly
positive for myeloperoxidase, CD43 and CD99 immunohistochemistry. Hemogram was normal. Bone
marrow aspiration/biopsy and CSF showed no evidence of acute myeloid leukemia. The child received
chemotherapy in another centre and is in complete remission 6 months after completion.A10-year-old boy presented with right propto-sis which had persisted for eight months.The eyeball was grossly pushed down, with
diffuse corneal haze and non-reactive pupil. Systemic
examination was normal. Previous investigations at
another center included a computerized tomography
scan, which showed a well-deﬁned enhancing retro-
bulbar mass (Figure 1), a non-contributory ﬁne needle
aspiration cytology and a biopsy showing ﬁbrocollag-
enous tissue with moderate lympho-monocytic inﬁl-
trate suggestive of non-speciﬁc inﬂammation.
A PET-CT scan revealed the presence of enlarged
ﬂuoro-deoxyglucose (FDG)-avid cervical and mesen-
teric lymph nodes. Biopsy of the retro-bulbar mass
was repeated at our center. It showed ﬁbrocollagenous
and skeletal muscle tissue inﬁltrated by lymphoid
follicles, dispersed lymphocytes and plasma cells, and
admixed large atypical cells with vesicular nuclei,Heprominent nucleoli and scanty cytoplasm, strongly
positive for myeloperoxidase, CD43 and CD99
immunohistochemistry (Figure 2).
Hemogram was normal. Bone marrow aspiration/
biopsy and CSF showed no evidence of acute myeloid
leukemia (AML). The child received chemotherapy at
another center and is in complete remission six
months after completion.DISCUSSION
Myeloid sarcomas are rare extramedullary manifesta-
tions of AML, with an estimated incidence of 2.5–
8% in AML.1 Orbital location is the most common.2
Myeloid sarcoma may be metachronous or synchro-
nous to leukemia. In the case of orbital location, bilat-
eral proptosis is slightly more frequent than unilateral
proptosis.3matol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
Figure 2. Orbital mass biopsy (A) Hematoxylin and eosin stain. (B) MPO, (C) CD 99 and (D) CD 43 immunostains are positive.
Figure 1. (A) Massive proptosis with eyeball pushed down grossly with restriction of motility, diffuse corneal haze and non reacting pupil. (B) CT scan of the orbit showing a
well defined enhancing mass in the right retrobulbar region.
ORBITAL MYELOID SARCOMA PRESENTING AS MASSIVE PROPTOSIS images and diagnosisThe prognostic implication of myeloid sarcoma is
unclear. Turkish reports show that AML patients
have poorer survival when orbital myeloid sarcomaHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comis present.4 However, US data showed that AML
children with orbital myeloid sarcoma have signiﬁ-
cantly better survival than those with isolated27
28
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AML.5 Possibly, orbital swelling leads to patients
seeking medical attention and referral to specialized
centers earlier, thus enabling early therapy and better
outcome. In lower income countries, late referrals are
common, leading to adverse outcome in most cancers,Heincluding AML.6 Despite delayed diagnosis, our pa-
tient is alive and disease-free.
AML should be considered in the differential diag-
nosis of an orbital mass, even in the absence of typical
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